TNFRSF11A and osteoporosis: The fundamental role of RANK signaling in osteoporosis and bone metastasis inspired the development of denosumab, a monoclonal antibody against RANKL, for the treatment of skeletal-related events (SREs) linked to osteoporosis and cancer [7].